Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Moderate to Severe Pemphigus (PV/PF)
2018-002261-19Phase 3Terminated
- Sponsor
- Principia Biopharma
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) comparing PRN1008 with Placebo (2 arms). Primary endpoint: Complete remission with minimal prednisone. Started Oct 2018; status: terminated.
02
Drugs
rilzabrutinib
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2018-002261-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002261-19.